BELLUS Health Inc.

• locale

  Canada

• market

  STOCKS

• industry

  Biotechnology

• website

  www.bellushealth.com

• ipo date

  Jun 22, 2000

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 199...Show More

*Estimate based on analyst consensus